December 2009 Volume 5, Issue 12

Volume 5, Issue 12 | December 2009

December 2009

In this Issue

Global News

Drug Discovery News Placeholder Image

Takeda, Amylin ink weighty deal

Companies in $1 billion-plus agreement to co-develop and commercialize compounds for obesity
Drug Discovery News Placeholder Image

Sanofi-aventis boosts oncology pipeline in deals with Oncodesign, Micromet

Deals aimed at boosting the French drug company’s pipeline and profile in cancer therapy market
Drug Discovery News Placeholder Image

Three’s a crowd

Lundbeck acquires French CMO and principal supplier Elaiapharm
Drug Discovery News Placeholder Image

Say ‘yes’ to nosocomial

MorphoSys and Daiichi Sankyo forge alliance to develop novel antibody therapies against hospital-acquired infections
Drug Discovery News Placeholder Image

Cross-pond collaboration

U.K., U.S. biotech trade groups join forces to promote industry

Research & Development

Drug Discovery News Placeholder Image

Shining a light on cancer

Two years into oncology research agreement, GE and Lilly develop technology to visualize and map complex biomarker networks
Drug Discovery News Placeholder Image

Tempting fate

Fate Therapeutics unveils creation of small-molecule program for commercial-scale reprogramming
Drug Discovery News Placeholder Image

Unbreak that heart

Gladstone and Stanford collaborate on developing IPS cells to repair damaged heart muscle
Drug Discovery News Placeholder Image

Partnering up for mutual gain

Quintiles forms strategic alliances with AstraZeneca and Eisai in back-to-back deals, following up on an earlier Allergan deal
Drug Discovery News Placeholder Image

Venturing into vaccines

TapImmune taps Crucell’s cell line for vaccine development
Drug Discovery News Placeholder Image

SurModics and NuPathe partner on long-acting Parkinson’s treatment

SurModics Inc., a provider of drug delivery and surface modification technologies to the healthcare industry, and NuPathe Inc., a neuroscience-focused specialty pharmaceutical company, announced in November that they signed a license agreement for NP201, the first long-acting treatment available in broadly acceptable dose form that maintains the potential to provide sustained relief from Parkinson’s disease without motor response complications.

Genomics & Proteomics

Drug Discovery News Placeholder Image

SuperGen CLIMBs on board with GSK

Companies will collaborate on development of novel epigenetic therapeutics
Drug Discovery News Placeholder Image

Show me the way

Dutch firm InteRNA Technologies and Dana-Farber Cancer Institute collaborate on the role of microRNAs in cancer pathways
Drug Discovery News Placeholder Image

The ‘Scout’ rounds up some business

Kinaxo secures deals with Roche, Bayer Vital and Janssen in October around its novel phosphoproteomics platform, PhosphoScout
Drug Discovery News Placeholder Image

1000 x 1000 human genomes in five years

Huntington’s disease project to sequence an unprecedented 100 human genomes in first six months
Drug Discovery News Placeholder Image

Partners in proteomics

Belgian firm Eurogentec expands its reach into the proteomics space with AnaSpec acquisition

Informatics

Drug Discovery News Placeholder Image

Peta-flogging HIV

Blazingly fast IBM-designed supercomputer is helping Los Alamos researchers focus on promising HIV vaccine targets
Drug Discovery News Placeholder Image

Perfect union

Thermo Fisher Watson LIMS and Symyx Notebook integrated to reduce bioanalytical workflow error and improve efficiency and reporting
Drug Discovery News Placeholder Image

Sifting through genes

Eurofins MWG Operon selects Geospiza's GeneSifter to automate DNA sequencing data analysis
Drug Discovery News Placeholder Image

In pursuit of the paperless clinical trial

IntraLinks announces Adobe-based paperless solution for clinical trial process

Commentary

Drug Discovery News Placeholder Image

Drug discovery paradigm could shift with cancer center involvement

Collaborations between data and computation-driven systems biology companies and forward-thinking oncology clinics are poised to change the face of cancer drug development and cancer itself.

Patent News

Drug Discovery News Placeholder Image

Supreme Court ponders what is patentable in Bilski case

Is Bilski important? Some estimates say as many as 200,000 patents could be invalidated if Bilski is held to strictly apply to all method patents. For the biotech industry, the decision has significant ramifications for the patentability of many inventions, particularly diagnostics and personalized medicine.

Editor's Focus

Drug Discovery News Placeholder Image

‘Twas the year of the M&A boom …

‘Twas the end of 2009, and in the ddn newsroom, the editors and writers gathered to reflect on Big Pharma’s M&A boom.

Automation & Instrumentation

Drug Discovery News Placeholder Image

Handy for growth

BD plans to acquire HandyLab to boost its molecular diagnostics offering
Drug Discovery News Placeholder Image

Nanoscale technology deal a tight fit

Agilent Technologies and Stanford University ink nanoscale collaboration deal
Drug Discovery News Placeholder Image

Epic developments are in the works

Corning and PerkinElmer collaborate on development of label-free detection technologies
Drug Discovery News Placeholder Image

Shedding labels

Caliper Life Sciences, SRU Biosystems to offer label-free services for cell-based and biochemical assays
Drug Discovery News Placeholder Image

Label-free: The way to be?

SBS hosts symposium on label-free technologies

New Products

Drug Discovery News Placeholder Image

Streamlined integration of pipetting with heating and shaking

Hamilton Robotics has introduced the MICROLAB NIMBUS Heater/Shaker Package, an integrated system that incorporates high-speed automated pipetting with orbital plate shaking and heating.
Drug Discovery News Placeholder Image

Sample preparation reagent provides reverse transcription-ready RNA in five minutes

Bio-Rad Laboratories Inc. has launched the iScript RT-qPCR Sample Preparation Reagent for rapid isolation of total RNA and enabling reverse transcription and real-time PCR to be performed directly from cell lysates.
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue